Adipotide
CKGGRAKDC-GG-D(KLAKLAK)2 · Prohibitin-targeting peptide · fat-destroying peptide
Adipotide is a radically aggressive, experimental peptidomimetic engineered to physically eradicate white adipose tissue. Rather than simply suppressing appetite like a GLP-1, it is designed to assassinate the very blood supply feeding fat cells. While it demonstrated shockingly rapid and massive fat loss in primate models, it is essentially a highly targeted biological weapon that carries profound, severe risks of renal toxicity and kidney damage.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight1.5/10
Primate fat-loss plus renal toxicity in the published file. Not a cutting peptide. Mechanism with a hard safety haircut.
Compound card
- Class
- Prohibitin-targeting peptidomimetic (CKGGRAKDC-GG-D(KLAKLAK)2 class)
- Formula
- Custom pro-apoptotic peptide
- Status
- Not FDA-approved · research use
How it works
Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) is a pro-apoptotic peptide that selectively targets the vasculature feeding white adipose tissue. It binds to prohibitin on the surface of fat blood vessels and delivers a cell-killing D(KLAKLAK)2 sequence, causing mitochondrial disruption and apoptosis of the endothelial cells supplying fat depots. This cuts off nutrient supply to adipocytes, causing fat cell death and rapid weight loss. Phase I/II primate studies showed 11% body weight reduction over 4 weeks - one of the most aggressive mechanisms of any anti-obesity agent.
Source: PMID: 22100857
Research Use Cases
- ✓Obesity (Preclinical Only): High
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Primate Research Dose | ~35 mg/kg | Daily for 4 weeks (IV, primate model) | No human clinical dose established. Research use only. |
Administration
Timeline
Who it is for
Obesity (Preclinical Only)
HighDramatic fat loss via vascular apoptosis mechanism - but renal toxicity observed in primates at therapeutic doses.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| 5 mg lyophilized | 2 mL BAC | 2.5 mg/mL | Do not community-dose this. Identity only. |
Change vial size or water volume? Open the reconstitution calculator.
Safety & Considerations
RESEARCH ONLY. Renal toxicity observed in primate studies at effective doses. No human clinical trials have been approved. Not for human use.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Renal injury is the reason this is not a toy.
- This site will not treat obesity from an adipotide page.
Verdict
Adipotide is a targeted pro-apoptotic peptidomimetic aimed at white-fat vasculature. Kidney toxicity showed up in animals. It is not a consumer fat-loss peptide.
Interactions & Contraindications
RESEARCH ONLY. Renal toxicity observed in primate studies at effective doses. No human clinical trials have been approved. Not for human use.
Frequently Asked Questions
Has adipotide been tested in humans?▼
How does adipotide differ from GLP-1 drugs?▼
References
- Kim DH et al. “"Targeted elimination of senescent cells by adipotide".” Science Translational Medicine (2011).
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code